NCT01511809View on ClinicalTrials.gov

Efficacy of Atazanavir/Ritonavir Monotherapy as Maintenance in Patients With Viral Suppression

PHASE3CompletedINTERVENTIONAL

Enrollment

117

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

July 31, 2013

Study Completion Date

May 31, 2015

Conditions

HIV-1 Infection

Interventions

DRUG

Atazanavir/ritonavir monotherapy

Monotherapy Simplification Strategy with Atazanavir/ritonavir 300/100 mg once daily for 96 weeks.

Trial Locations (1)

20127

Infectious Diseases Department Fondazione Centro San Raffaele, Milan

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

IRCCS San Raffaele

OTHER